Latest European Expansion News

Electro Optic Systems (EOS) addresses rumours about relocating its headquarters and stock listing to Europe, affirming no such decisions have been made despite strong growth in European defence markets.

International Graphite Limited has secured key approvals and funding to progress its Collie Micronising Facility and European Expandable Graphite Project, positioning itself as a major supplier outside China.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Sprintex Limited has landed its largest-ever €15.6 million order for ZLD-UP® manure processing systems, marking a pivotal shift from evaluation to commercial deployment across Europe. This multi-year contract sets the stage for substantial revenue growth and a path to profitability in FY26.

Collins Foods Limited has reported record half-year revenues of $750.3 million, with underlying net profit after tax surging 29.5%. The company’s operational improvements and expansion in Europe underpin an upgraded FY26 outlook.

South Harz Potash Limited (SHP) has secured an option to acquire the Glava copper-gold project in Sweden, complementing its advanced potash development in Germany and reinforcing its multi-commodity European strategy.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.